A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants.
Immune
Immunization
Infant
Maternal vaccination
Pregnancy
Response
Vaccine
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
21
01
2021
accepted:
11
05
2021
entrez:
8
6
2021
pubmed:
9
6
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Pertussis vaccines containing three or five pertussis antigens are recommended in pregnancy in many countries, but no studies have compared the effect on infants' antigen-specific immunoglobulin G (IgG) concentrations. The aim of this study was to compare anti-pertussis IgG responses following primary immunization in infants of mothers vaccinated with TdaP This multi-centre phase IV randomized clinical trial was conducted in a tertiary referral centre and primary care sites in England. Women were randomized to receive TdaP Following infant primary immunization, there was no difference in the geometric mean concentrations (GMCs) of anti-pertussis toxin, filamentous haemagglutinin or pertactin IgG between infants born to women vaccinated with TdaP Blunting of anti-pertussis toxin IgG response following primary immunization occurs in infants born to women vaccinated with TdaP ClinicalTrials.gov , NCT02145624 , registered 23 May 2014.
Sections du résumé
BACKGROUND
Pertussis vaccines containing three or five pertussis antigens are recommended in pregnancy in many countries, but no studies have compared the effect on infants' antigen-specific immunoglobulin G (IgG) concentrations. The aim of this study was to compare anti-pertussis IgG responses following primary immunization in infants of mothers vaccinated with TdaP
METHODS
This multi-centre phase IV randomized clinical trial was conducted in a tertiary referral centre and primary care sites in England. Women were randomized to receive TdaP
RESULTS
Following infant primary immunization, there was no difference in the geometric mean concentrations (GMCs) of anti-pertussis toxin, filamentous haemagglutinin or pertactin IgG between infants born to women vaccinated with TdaP
CONCLUSION
Blunting of anti-pertussis toxin IgG response following primary immunization occurs in infants born to women vaccinated with TdaP
TRIAL REGISTRATION
ClinicalTrials.gov , NCT02145624 , registered 23 May 2014.
Identifiants
pubmed: 34098951
doi: 10.1186/s12916-021-02005-5
pii: 10.1186/s12916-021-02005-5
pmc: PMC8186138
doi:
Substances chimiques
Antibodies, Bacterial
0
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Poliovirus Vaccine, Inactivated
0
Banques de données
ClinicalTrials.gov
['NCT02145624']
Types de publication
Clinical Trial, Phase IV
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
138Références
Vaccine. 2016 Apr 29;34(20):2349-53
pubmed: 27013434
Pediatrics. 2017 May;139(5):
pubmed: 28557752
Euro Surveill. 2013 Sep 19;18(38):
pubmed: 24084340
J Infect Dis. 2004 Jul 15;190(2):335-40
pubmed: 15216470
Clin Infect Dis. 2017 Nov 29;65(12):1977-1983
pubmed: 29028938
BMJ Open. 2016 Apr 18;6(4):e010911
pubmed: 27091823
JAMA. 2014 Nov 12;312(18):1897-904
pubmed: 25387187
Clin Infect Dis. 2017 Jan 1;64(1):9-14
pubmed: 27624956
Clin Infect Dis. 2015 Feb 1;60(3):333-7
pubmed: 25332078
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S197-S204
pubmed: 27838673
Clin Infect Dis. 2018 Sep 14;67(7):1063-1071
pubmed: 30010773
Vaccine. 1998 Dec;16(20):1907-16
pubmed: 9796042
Vaccine. 2018 Mar 27;36(14):1887-1892
pubmed: 29501321
Lancet Infect Dis. 2007 Sep;7(9):614-24
pubmed: 17537674
Vaccine. 1998 Dec;16(20):1901-6
pubmed: 9796041
Pediatr Infect Dis J. 2013 Nov;32(11):1257-60
pubmed: 23799518
Vaccine. 2016 Jan 2;34(1):142-50
pubmed: 26592142
Vaccine. 2017 Jul 24;35(33):4072-4078
pubmed: 28669620
Vaccine. 2018 Aug 16;36(34):5173-5179
pubmed: 30031662
Lancet Infect Dis. 2019 Apr;19(4):392-401
pubmed: 30938299
Vaccine. 2016 Jun 30;34(31):3613-9
pubmed: 27142328
BMJ. 2014 Jul 11;349:g4219
pubmed: 25015137
Clin Infect Dis. 2015 Dec 1;61(11):1637-44
pubmed: 26374816
Euro Surveill. 2017 Jun 1;22(22):
pubmed: 28598324
Lancet. 2014 Oct 25;384(9953):1521-8
pubmed: 25037990
Vaccine. 2016 Dec 7;34(50):6223-6228
pubmed: 27847175
Obstet Gynecol. 2015 Jun;125(6):1433-1438
pubmed: 26000515
Clin Infect Dis. 2017 Jan 1;64(1):3-8
pubmed: 27624955
Am J Reprod Immunol. 1996 Nov;36(5):248-55
pubmed: 8955500
J Infect Dis. 2000 Mar;181(3):1010-3
pubmed: 10720524
Vaccine. 2015 Jan 29;33(5):648-55
pubmed: 25510388
Clin Exp Immunol. 2019 Jul;197(1):1-10
pubmed: 30758857
Hum Vaccin Immunother. 2016 Aug 2;12(8):1965-1971
pubmed: 27002930
JAMA. 2015 Oct 20;314(15):1581-7
pubmed: 26501534
Vaccine. 2016 Jan 2;34(1):151-9
pubmed: 26529073
JAMA. 2014 May 7;311(17):1760-9
pubmed: 24794369
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S236-S243
pubmed: 27838678